Advertisement
Screener

FATE THERAPEUTICS INC (FATE) Graph

FATE Revenue Flow

Filed revenue amounts for 2026-04-01 to 2026-06-30. Coverage is partial. Unconnected amounts are separate disclosures; they must not be added together.

  • 2026-06-30: Revenue $2.08M; Research and development $24.39M; Operating expenses $33.22M; Net income -$30.16M.
  • 2026-03-31: Revenue $1.30M; Research and development $24.70M; Operating expenses $34.30M; Net income -$31.21M.
  • 2025-12-31: Revenue $1.37M*; Research and development $25.43M*; Operating expenses $36.09M*; Net income -$32.37M*.
  • 2025-09-30: Revenue $1.74M; Research and development $25.84M; Operating expenses $36.48M; Net income -$32.25M.

Consolidation item

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

FATE revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Operating Segments$2.08MRevenue$2.08MOperating expenses$33.22MOperating income-$31.13MOther income, net$975.00KResearch & development$24.39M

Counterparty Name

Separate filed amounts; connecting flows are not established. Components and totals may overlap.

FATE revenue flowFiled amounts. Only explicit calculation relationships connect amounts; dimensional membership alone does not establish an additive flow.Ono PharmaceuticalCompany Ltd$2.10MRevenue$2.08MOperating expenses$33.22MOperating income-$31.13MOther income, net$975.00KResearch & development$24.39M

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesNet income
2026-06-30$2.08M$24.39M$33.22M-$30.16M
2026-03-31$1.30M$24.70M$34.30M-$31.21M
2025-12-31$1.37M*$25.43M*$36.09M*-$32.37M*
2025-09-30$1.74M$25.84M$36.48M-$32.25M
2025-06-30$1.91M$27.43M$38.88M-$34.07M
2025-03-31$1.63M$29.14M$42.91M-$37.62M
2024-09-30$3.07M$34.65M$55.45M-$47.68M
2024-06-30$6.77M$34.60M$51.85M-$38.43M
2024-03-31$1.93M$32.14M$52.99M-$48.00M
2023-09-30$1.94M$34.27M$53.22M-$45.17M
2023-06-30$933.00K$40.88M$63.50M-$52.76M
2023-03-31$58.98M$65.63M$87.57M-$18.88M
2022-09-30$14.98M$79.82M$101.37M-$83.56M
2022-06-30$18.55M$81.31M$101.66M-$76.11M
2022-03-31$18.41M$72.14M$92.88M-$65.69M
2021-09-30$14.22M$53.13M$68.85M-$43.31M
2021-06-30$13.41M$48.02M$60.19M-$55.13M
2021-03-31$11.14M$44.85M$57.35M-$45.09M
2020-09-30$7.56M$30.69M$39.05M-$58.68M
2020-06-30$5.46M$26.67M$34.17M-$28.07M
2020-03-31$2.52M$29.28M$37.01M-$33.52M
2019-12-31$2.80M(m)$31.88M-$28.30M
2019-09-30$2.43M$23.20M$29.55M-$26.61M
2019-06-30$2.82M$21.63M$26.90M-$23.48M
2019-03-31$2.63M$17.73M$23.08M-$19.76M
2018-12-31$1.66M(m)$18.40M-$16.03M
2018-09-30$1.03M$13.64M$17.72M-$16.78M
2018-06-30$1.03M$16.82M$20.63M-$19.65M
2018-03-31$1.03M$11.48M$15.08M-$14.13M
2017-12-31$1.03M(m)$13.27M-$12.50M
2017-09-30$1.03M$8.58M$11.37M-$10.68M
2017-06-30$1.03M$7.93M$10.60M-$9.64M
2017-03-31$1.03M$7.97M$11.00M-$10.13M
2016-12-31$1.03M(m)$8.68M-$7.94M
2016-09-30$1.03M$6.80M$9.41M-$8.74M
2016-06-30$1.03M$6.78M$9.03M-$8.41M
2016-03-31$1.32M$6.64M$9.24M-$8.38M
2015-12-31$1.08M(m)$7.99M-$7.45M
2015-09-30$1.03M$5.00M$7.35M-$6.89M
2015-06-30$329.00K$4.86M$7.55M-$7.78M
2015-03-31(m)$4.57M$7.32M-$7.88M
2014-12-31(m)(m)$5.94M-$6.23M
2014-09-30(m)$4.08M$5.98M-$6.60M
2014-06-30(m)$3.97M$6.04M-$6.07M
2014-03-31(m)$4.52M$6.94M-$6.98M
2013-12-31(m)(m)$4.90M-$5.74M
2013-09-30$209.00K$3.38M$5.36M-$6.07M
2013-06-30$290.00K$3.07M$4.56M-$5.53M
2013-03-31$472.00K$2.53M$3.83M-$3.55M
2012-12-31$643.00K(m)$4.69M-$4.16M
2012-09-30$528.00K$3.31M$4.18M-$4.11M
2012-06-30$1.08M(m)$3.82M-$2.74M
2012-03-31$418.00K(m)$3.54M-$3.23M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesNet income
2026-06-30$3.38M$49.09M$67.52M-$61.37M
2025-06-30$3.54M$56.57M$81.78M-$71.69M
2024-06-30$8.70M$66.74M$104.85M-$86.43M
2023-06-30$59.91M$106.50M$151.07M-$71.64M
2022-06-30$36.96M$153.45M$194.54M-$141.79M
2021-06-30$24.55M$92.87M$117.54M-$100.22M
2020-06-30$7.98M$55.95M$71.18M-$61.59M
2019-06-30$5.45M$39.36M$49.98M-$43.24M
2018-06-30$2.05M$28.29M$35.71M-$33.79M
2017-06-30$2.05M$15.89M$21.59M-$19.77M
2016-06-30(m)$13.42M$18.27M-$16.79M
2015-06-30(m)$9.43M$14.87M-$15.66M
2014-06-30(m)$8.49M$12.98M-$13.05M
2013-06-30$762.00K$5.60M$8.39M-$9.08M

Revenue and expense 8 month

Period endNet income
2007-12-31-$1.22M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesNet income
2025-09-30$5.28M$82.40M$118.26M-$103.94M
2024-09-30$11.77M$101.39M$160.30M-$134.11M
2023-09-30$61.86M$140.78M$204.29M-$116.81M
2022-09-30$51.94M$233.26M$295.91M-$225.36M
2021-09-30$38.78M$146.00M$186.39M-$143.53M
2020-09-30$15.54M$86.64M$110.22M-$120.28M
2019-09-30$7.88M$62.56M$79.53M-$69.85M
2018-09-30$3.08M$41.93M$53.43M-$50.57M
2017-09-30$3.08M$24.47M$32.96M-$30.45M
2016-09-30(m)$20.22M$27.68M-$25.52M
2015-09-30(m)$14.43M$22.23M-$22.55M
2014-09-30(m)$12.57M$18.96M-$19.65M
2013-09-30$971.00K$8.98M$13.74M-$15.15M
2012-09-30$2.03M$8.60M$11.54M-$10.08M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$6.65M$107.83M$154.35M$2.00K-$136.31M
2024-12-31$13.63M$135.00M$223.91M$0.00-$186.26M
2023-12-31$63.53M$172.60M$254.04M$0.00-$160.93M
2022-12-31$96.30M$320.45M$404.69M$0.00-$281.72M
2021-12-31$55.85M$215.52M$272.84M$0.00-$212.15M
2020-12-31$31.43M$125.62M$159.52M$0.00-$173.39M
2019-12-31$10.68M$87.77M$111.41M$0.00-$98.15M
2018-12-31$4.74M$56.02M$71.83M(m)-$66.60M
2017-12-31$4.11M$34.36M$46.23M(m)-$42.95M
2016-12-31$4.40M$26.45M$36.37M(m)-$33.46M
2015-12-31$2.43M$19.86M$30.21M(m)-$29.99M
2014-12-31(m)$16.43M$24.90M(m)-$25.88M
2013-12-31$971.00K$12.01M$18.65M(m)-$20.89M
2012-12-31$2.67M$12.00M$16.23M(m)-$14.24M
2011-12-31$1.17M$9.86M$14.46M(m)-$13.43M
2010-12-31(m)(m)(m)(m)-$16.22M
2009-12-31(m)(m)(m)(m)-$13.33M
2008-12-31(m)(m)(m)(m)-$7.17M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Liminatus Pharma, Inc. (LIMN)United States$0.282B
Lexeo Therapeutics, Inc. (LXEO)United States$0.278B-4.19
PALISADE BIO, INC. (PALI)United States$0.275B-11.41
Invivyd, Inc. (IVVD)United States$0.270B-2.42
Inhibikase Therapeutics, Inc. (IKT)United States$0.296B-4.44
X4 Pharmaceuticals, Inc (XFOR)United States$0.297B-4.99
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
SAB Biotherapeutics, Inc. (SABS)United States$0.306B-25.49
Century Therapeutics, Inc. (IPSC)United States$0.306B-4.02
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35